INCY Incyte Corporation

120.49
+0.31  (0.26%)
Previous Close 120.18
Open 120.18
Price To book 54.04
Market Cap 22.72B
Shares 188,598,000
Volume 941,388
Short Ratio 2.83
Av. Daily Volume 1,360,190

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Pivotal program expected to begin in 2017.
Itacitinib (JAK1)
Treatment-naïve acute GVHD
Phase 3 trial to be initiated in 2017.
Baricitinib
Psoriatic arthritis
Phase 2 expected to begin in 1H 2017.
INCB50465 (CITADEL-202)
Diffuse large B cell lymphoma
Pivotal program to commence in 2017.
Ruxolitinib
Essential thrombocythemia
Phase 3 trial to commence in 2017.
Ruxolitinib - REACH 3
Steroid-refractory chronic GVHD (Graft versus host disease)
Phase 3 trial to commence in 2017.
Ruxolitinib - REACH 2
Steroid-refractory acute GVHD (Graft versus host disease)
Phase 3 planned.
Epacadostat with Keytruda
Squamous cell carcinoma of the head and neck cancer
Phase 3 planned.
Epacadostat with Keytruda
Bladder cancer
Phase 3 planned.
Epacadostat with Keytruda
Non-small cell lung cancer (NSCLC)
Announced January 19 2016 NDA filing by partner Eli Lilly. Noted January 13 2017 that its PDUFA date has been extended three months. Estimate April 14, 2017.
Baricitinib
Rheumatoid arthritis
Phase 2 initiated October 2015
Ruxolitinib cream
Topical treatment of alopecia areata
Approved December 4 2014
Jakafi (ruxolitinib) (RESPONSE)
Polycythemia Vera
Phase 3 initiated June 2016. Initial data due 2018
Epacadostat with Keytruda - ECHO-301
Cancer - first-line metastatic melanoma.
Phase 1/2 in combination with osimertinib (EGFR) expected to initiate 4Q 2016.
INCB39110 with osimertinib (EGFR)
Lung cancer
Ongoing
Epacadostat
Cancer - multiple tumor types
Endpoint not met, mid-2014
Jakafi (ruxolitinib) (RELIEF)
Disease-related symptoms in patients with Polycythemia Vera
Phase 2 trial stopped January 2016 due to lack of efficacy
Ruxolitinib
Colorectal cancer
Phase 3 trial discontinued due to lack of efficacy
Ruxolitinib - JANUS 1 and JANUS 2
Cancer - Pancreatic
Phase 3 to be initiated 4Q 2016.
Ruxolitinib
Graft versus host disease

Latest News

  1. Incyte to Present at Upcoming Investor Conferences
  2. INCYTE CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, F
  3. INCYTE CORP Financials
  4. Merck, Bristol-Myers, Incyte Race For A Cure In $25 Billion I-O Market
  5. NetEase Delivers Nice Option Win; Mobileye, Tesla, InterDigital On Deck
  6. Incyte Corp. :INCY-US: Earnings Analysis: 2016 By the Numbers : February 16, 2017
  7. Additional results from pivotal RA-BEAM study published in New England Journal of Medicine show baricitinib-treated patients demonstrated sustained improvement in rheumatoid arthritis compared to adalimumab and placebo
  8. Additional results from pivotal RA-BEAM study published in New England Journal of Medicine show baricitinib-treated patients demonstrated sustained improvement in rheumatoid arthritis compared to adalimumab and placebo
  9. Softness in Incyte Should Be Short-Lived, if Our Quants Are Right
  10. Incyte's (INCY) Beats on Q4 Earnings, Provides 2017 Outlook
  11. Incyte Corp. :INCY-US: Earnings Analysis: Q4, 2016 By the Numbers : February 15, 2017
  12. Biotech Stock Roundup: Regeneron's Praluent to Remain on Market for Now, GILD Presents HIV Data
  13. INCYTE CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial State
  14. Incyte Q4 Revenue Tops Views, Though Jakafi Sales Narrowly Miss
  15. Incyte 4Q Earnings $9 Million or 5 Cents a Share
  16. Edited Transcript of INCY earnings conference call or presentation 14-Feb-17 3:00pm GMT
  17. ​Lexington-based Agenus reworks Incyte pact, freeing up $80M in cash
  18. Incyte and Agenus Amend Drug Licensing Deal
  19. Incyte Q4 Revenue Tops Views, Though Jakafi Sales Narrowly Miss
  20. Why Agenus Stock Is Surging Today